Practical clinical use of therapeutic agents for Alzheimer's disease

Folia Pharmacologica Japonica

Volumn 130, Issue 6, 2007, Pages 494-498

  Arai, Tetsuaki ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; BAPINEUZUMAB; GINKGO BILOBA EXTRACT; HOMOTAURINE; N METHYL DEXTRO ASPARTIC ACID; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TARENFLURBIL; CHOLINESTERASE INHIBITOR; DONEPEZIL; INDAN DERIVATIVE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PIPERIDINE DERIVATIVE;

ALZHEIMER DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DEMENTIA; GINKGO BILOBA; HUMAN; NEUROIMAGING; NEUROPSYCHIATRY; REVIEW; BEHAVIOR; CLASSIFICATION; COGNITIVE DEFECT; DRUG ANTAGONISM;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; HUMANS; INDANS; MEMANTINE; PIPERIDINES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 39549088962     PISSN: 00155691     EISSN: 13478397     Source Type: Journal    
DOI: 10.1254/fpj.130.494     Document Type: Review

References (34)

1. Finkel SI, et al. Int Psychogeriatr. 1996;8 Suppl 3:497-500.
2. Japanese source
3. Japanese source
4. Lyketsos CG, et al. Am J Psychiatry. 2000;157:708-714.
5. Ikeda M, et al. J Neurol Neurosurg Psychiatry. 2004;75:146-148.
6. Farlow MR, et al. Am J Med. 2007;120:388-397.
7. Winblad B, et al. Lancet. 2006;367:1057-1065.
8. Black SE, et al. Neurology. 2007;69:459-469.
9. Beier MT. Am J Health Syst Pharm. 2007;64:S9-17.
10. Japanese source
11. McGeer PL, et al. J Alzheimers Dis. 2006;9 3 Suppl:271-276.
12. Nakamura S. Intern Med. 2004;43:18-29.
13. Japanese source
14. Katz IR, et al. Risperidone Study Group. J Clin Psychiatry. 1999;60:107-115.
15. Shigenobu K, et al. Int J Geriatr Psychiatry. 2002;17:211-217.
16. Street JS, et al. The HGEU Study Group. Arch Gen Psychiatry. 2000;57:968-976.
17. Tariot PN, et al. Am J Geriatr Psychiatry. 2006;14:767-776.
18. De Deyn P, et al. J Clin Psychopharmacol. 2005;25:463-467.
19. Schneider LS, et al. N Engl J Med. 2006;355:1525-1538.
20. Cruzan S. FDA Talk Paper April 11. 2005.
21. Wang PS, et al. N Engl J Med. 2005;353:2335-2341.
22. Robert PH, Eur Psychiatry. 2001;16:S42-S47.
23. Iwasaki K, et al. J Clin Psychiatry. 2005;66:248-252.
24. Sato S, et al. Int J Neuropsychopharmacol. 2007;10:281-283.
25. Japanese source
26. Tariot PN, et al. Am J Psychiatry. 1998;155:54-61.
27. Tariot PN, et al. Int Psychogeriatr. 2000;12 Suppl 1:237-244.
28. Thompson S, et al. Can J Psychiatry. 2007;52:248-255.
29. Olin JT, et al. Am J Geriatr Psychiatry. 2002;10:129-141.
30. Starkstein SE, et al. Expert Rev Neurother. 2006;6:887-895.
31. Mizukami K, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1342-1346.
32. Masuda Y, et al. Hum Psychopharmacol. 2002;17:191-193.
33. Cummings JL, et al. Am J Geriatr Psychiatry. 2006;14:605-612.
34. Rozzini L, et al. Aging Clin Exp Res. 2006;19:220-223.